Clinical trials
Castration Sensitive Prostate Cancer clinical trials
Below are recruiting castration sensitive prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06244004RecruitingPhase 2
PET-guided radiation for metastatic hormone-sensitive prostate cancer
This trial tests whether using a special PET scan (FDG-PET) to find and treat only the spots where cancer has spread with targeted radiation can help men with prostate cancer that has spread but still responds to hormone therapy. It compares standard treatment alone to standard treatment plus this targeted radiation.
Chicago, IllinoisAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06392295RecruitingPhase 2
PSMA-Guided Radiation for Limited Prostate Cancer Return
This trial tests whether targeted radiation to the lymph nodes in the belly can help men whose prostate cancer has returned in just a few spots after prior radiation. You must have had a PSMA PET/CT scan showing the cancer is limited to pelvic or belly lymph nodes.
Miami, FloridaAges 18 years+ - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Fayetteville, ArkansasAges 18 years+ - NCT06473259Recruiting
Comparing treatments for hormone-sensitive metastatic prostate cancer
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Orbassano, TorinoAges Any age - NCT07691697Recruiting
PSMA PET-guided radiation for slowing prostate cancer growth
This trial uses a special scan called PSMA PET to find and treat a small number of cancer spots that are growing while you are on standard treatment. The goal is to give precise radiation to those spots to help keep the rest of the cancer under control.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06652607Recruiting
PSA response as a sign of treatment success in prostate cancer
This trial is for men with prostate cancer that has spread to other parts of the body and is being treated with hormone therapy. It looks at whether a drop in PSA levels after six months can help predict how well the treatment is working.
Rome, LazioAges 18 years+ - NCT06705686RecruitingPhase 1
New drug for advanced prostate cancer
This trial tests an experimental drug called (R)-9b for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can help control the cancer.
Madison, WisconsinAges 18 years+ - NCT07406282Recruiting
Darolutamide for new prostate cancer that spread
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
Cleveland, OhioAges 18 years+ - NCT06835218Recruiting
Prostate cancer real-world evidence registry
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06879041RecruitingPhase 1
Study of a radiation drug for advanced prostate cancer
This trial tests a new drug that delivers radiation directly to cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07190300RecruitingPhase 1/Phase 2
Testing tulmimetostat with hormone therapy for metastatic prostate cancer
This trial tests a new drug, tulmimetostat, combined with standard hormone therapies like darolutamide or abiraterone for men with metastatic prostate cancer that still responds to hormone treatment. The goal is to see if the combination works better than standard therapy alone.
Birmingham, AlabamaAges 18 years+ - NCT07252726RecruitingPhase 4
Morning vs. evening dosing for metastatic breast or prostate cancer
This trial tests whether taking your hormone therapy and targeted pills in the morning or evening affects how well they work and how you feel. It is for people with metastatic breast or prostate cancer starting a specific hormone-based treatment combination.
Kitchener, OntarioAges 18 years+ - NCT07260435RecruitingPhase 3
Shorter hormone treatment for low volume spread prostate cancer
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
AlkmaarAges 18 years+ - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT07451002Recruiting
Study on Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
CaenAges 18 years+ - NCT05582772Recruiting
Supportive care for older men with metastatic prostate cancer
This study tests a phone-based supportive care program for older men with prostate cancer. It aims to help with day-to-day management while you’re receiving hormone-related cancer treatment.
Toronto, OntarioAges 65 years+ - NCT07529717RecruitingPhase 1/Phase 2
Early-stage study of AZD8359 for advanced prostate cancer
This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.
Orlando, FloridaAges 18–100 - NCT07354919RecruitingPhase 2
Testing axelopran for advanced cancer patients on opioids
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Saint Louis Park, MinnesotaAges 18 years+ - NCT06582628RecruitingPhase 2
Talazoparib and enzalutamide after abiraterone in prostate cancer
This trial tests two drugs—talazoparib and enzalutamide—given together to men whose metastatic prostate cancer has worsened after treatment with abiraterone (Zytiga). The goal is to see if this combination can help control the cancer.
Badalona, BarcelonaAges 18 years+
Hear when a new Castration Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for castration sensitive prostate cancer?
- Yes. Clin2 currently lists 93 recruiting castration sensitive prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a castration sensitive prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a castration sensitive prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Hormone Sensitive Prostate Cancer
- Castrate Sensitive Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Castration-Sensitive Prostate Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.